Methyl-p-hydoxyphenyllactate-esterase activity in breast cancer: A potentially new prognostic factor in short-term follow-up

Cancer Research

Volumn 57, Issue 23, 1997, Pages 5406-5409

  Carbone, Arnaldo ^a   Serra, Fabio Giosuè ^a   Ferrandina, Gabriella ^a   Scambia, Giovanni ^a   Terribile, Daniela ^b   Bellantone, Rocco ^b   Piantelli, Mauro ^c   Ranelletti, Franco Oreste ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTERASE; CARBOXYLESTERASE; ESTROGEN RECEPTOR; METHYL P HYDROXYPHENYLLACTATE ESTERASE; METHYL-P-HYDROXYPHENYLLACTATE ESTERASE; PROGESTERONE RECEPTOR; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL GROWTH; ENZYME ACTIVITY; ENZYME ASSAY; FOLLOW UP; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROGNOSIS; ADULT; AGED; ANALYSIS OF VARIANCE; BREAST TUMOR; ENZYMOLOGY; FEMALE; LYMPH NODE METASTASIS; LYMPHADENECTOMY; METABOLISM; METASTASIS; MIDDLE AGED; MITOSIS INDEX; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; POSTMENOPAUSE; PREMENOPAUSE; REGRESSION ANALYSIS; SURVIVAL RATE; TIME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CARBOXYLIC ESTER HYDROLASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MIDDLE AGED; MITOTIC INDEX; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; POSTMENOPAUSE; PREMENOPAUSE; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGRESSION ANALYSIS; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030609011     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Clark, J. H., Hardin, J. W., and Upchurch, S. Heterogeneity of estrogen-binding sites in the cytosol of rat uterus. J. Biol. Chem., 253: 7630-7634, 1978.
2. Syne, J. S., Markaverich, B. M., Clark, J. H., and Panko, W. B. Estrogen binding sites in the nucleus of normal and malignant human tissue: characteristics of the multiple nuclear binding sites. Cancer Res., 42: 4449-4454, 1982.
3. Ranelletti, F. O., Piantelli, M., Carbone, A., Rinelli, A., Scambia, G., Benedetti Panici, P., and Mancuso, S. Type II estrogen binding sites and 17β-hydroxysteroid dehydrogenase activity in human peripheral blood mononuclear cells. J. Clin. Endocrinol. Metab., 67: 888-892, 1988.
4. Ranelletti, F. O., Ricci, R., Larocca, L. M., Maggiano, N., Capelli, A., Scambia, G., Benedetti Panici, P., Mancuso, S., Rumi, C., and Piantelli, M. Growth-inhibitory effect of quercetin and presence of type II estrogen-binding sites in human colon cancer cell lines and primary colorectal tumors. Int. J. Cancer, 50: 486-492, 1992.
5. Piantelli, M., Rinelli, A., Macri, E., Maggiano, N., Larocca, L. M., Scerrati, M., Roselli, R., Iacoangeli, M., Scambia, G., Capelli, A., and Ranelletti, F. O. Type II estrogen-binding sites and anti-proliferative activity of quercetin in human meningiomas. Cancer (Phila.), 71: 193-198, 1993.
6. Ferrandina, G., Scambia, G., Benedetti Panici, P., Ranelletti, F. O., De Vincenzo, R., Piantelli, M., Distefano, M., Capelli, A., and Mancuso, S. Type II estrogen-binding sites in human ovarian cancer: correlation with estrogen, progesterone and epidermal growth factor receptor. Gynecol. Oncol., 49: 67-72, 1993.
7. Markaverich, B. M., Roberts, R. R., Alejandro, M. A., Johnson, G. A., Middleditch, B. S., and Clark, J. H. Bioflavonoid interaction with rat uterine type II binding sites and cell growth inhibition. J. Steroid Biochem., 30: 71-78, 1988.
8. Scambia, G., Ranelletti, F. O., Benedetti Panici, P., Piantelli, M., Bonanno, G., De Vincenzo, R., Ferrandina, G., Rumi, C., Larocca, L. M., and Mancuso, S. Inhibitory effects of quercetin on OVCA 433 cells and the presence of type II oestrogen binding sites in primary ovarian tumors and cultured cells. Br. J. Cancer, 62: 942-946, 1990.
9. Scambia, G., Ranelletti, F. O., Benedetti Panici, P., Piantelli, M., Bonanno, G., De Vincenzo, R., Ferrandina, G., Pierelli, L., Capelli, A., and Mancuso, S. Type II estrogen binding sites in a Iymphoblastoid cell line and growth inhibitory effects of estrogen, antiestrogen, and bioflavonoids. Int. J. Cancer, 46: 1112-1116, 1990.
10. Scambia, G., Ranelletti, F. O., Benedetti Panici, P., Piantelli, M., Bonanno, G., De Vincenzo, R., Ferrandina, G., Pierelli, L., Capelli, A., and Mancuso, S. Quercetin inhibits the growth of multidrug-resistant estrogen receptor-negative MCF-7 human breast cancer cell line expressing type II estrogen-binding sites. Cancer Chemother. Pharmacol., 28: 255-258, 1991.
11. Scambia, G., Ranelletti, F. O., Benedetti Panici, P., Piantelli, M., De Vincenzo, R., Ferrandina, G., Bonanno, G., Capelli, A., and Mancuso, S. Quercetin induces type II estrogen-binding sites in estrogen receptor-negative (MDA-MB231) and estrogen receptor-positive (MCF-7) human breast cancer cell lines. Int. J. Cancer. 54: 462-466, 1993.
12. Griffiths, L. A., and Smith, G. E. Metabolism of apigenin and related compounds in the rat. Biochem. J., 128: 901-911, 1972.
13. Karoum, F. On the origin of central and peripheral p-hydroxyphenylacetic acid in rats: a comparison with metabolites of biogenic amines other than p-tyramine. Biog. Amines. 2: 269-282, 1985.
14. 3H]estradiol binding in rat uterine nuclei. J. Biol. Chem., 258: 11663-11671, 1983.
15. 3H]estradiol binding in normal and malignant tissues. Cancer Res., 44: 1515-1519, 1984.
16. Markaverich, B. M., Gregory, R. R., Alejandro, M. A., Clark, J. H., Johnson, G. A., and Middleditch, B. S. Methyl-p-hydroxyphenyllactate: an inhibitor of cell growth and proliferation and an endogenous ligand for nuclear type II binding sites. J. Biol. Chem., 263: 7203-7210, 1988.
17. Markaverich, B. M., Gregory, R. R., Alejandro, M. A., Kittrell, F. S., Medina, D., Clark, J. H., Varma, M., and Varma, R. S. Methyl-p-hydroxyphenyllactate and nuclear type II binding sites in malignant cells: metabolic fate and mammary tumor growth. Cancer Res., 50: 1470-1478, 1990.
18. Markaverich, B. M., Schauweker, T. H., Gregory, R. R., Varma, M., Kittrell, F. S., Medina, D., and Varma, R. S. Nuclear type II sites and malignant cell proliferation: inhibition by 2,6-bis-benzylidenecyclohexanones. Cancer Res., 52: 2482-2488, 1992.
19. Markaverich, B. M., Gregory, R. R., Alejandro, M. A., Varma, R. S., Johnson, G. A., and Middleditch, B. S. Estrogen regulation of methyl-p-hydroxyphenyllactate hydrolysis: correlation with estrogen stimulation of rat uterine growth. J. Steroid Biochem., 33: 867-876, 1989.
20. Maybruck, W. M., and Markaverich, B. M. Partial purification and characterization of methyl-p-hydroxyphenyllactate esterase in rat uterine cytosol. Steroids, 62: 321-330, 1997.
21. WHO. Histological Typing of Breast Tumours, 2nd ed., International Histological Classification of Tumours No. 2. Geneva: WHO, 1981.
22. Dixon, J. M., Anderson, T. J., Page, D. L., Lee, D., and Duffy, S. W. Infiltrating lobular carcinoma of the breast. Histopathology (Oxf.), 6: 149-161, 1982.
23. Page, D. L., and Anderson, T. J. Diagnostic Histopathology of the Breast. London: Churchill Livingstone, 1987.
24. Bloom, H. J. G., and Richardson, W. W. Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br. J. Cancer, 11: 359-377, 1957.
25. Fisher, B., Redmond, C., Fisher, E. R., and Caplan, R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node native breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J. Clin. Oncol., 6: 1076-1087, 1988.
26. Baak, J. P. A., van Dop, H., Kurver, P. H. J., and Hermans, J. The value of morphometry to classic prognosticators in breast cancer. Cancer (Phila.), 56: 374-382, 1985.
27. Carbone, A., and Vecchio, F. M. Presence of cytoplasmic progesterone receptors in hepatic adenomas. Report of two cases. Am. J. Clin. Pathol., 85: 325-329, 1986.
28. Piffanelli, A., Fumero, S., Pelizzola, D., Berruto, G. P., Ricci, L., and Giovannini, G. Protocollo del metodo con Charcoal-destrano (DCC) per il dosaggio dei recettori dell'estradiolo e del progesterone nel tessuto neoplastico. LAB, J. Res. Lab. Med., IX: 13-21, 1982.
29. Thornthwaite, J. T., and Thomas, R. A. High-resolution DNA measurements using the nuclear isolation medium-DAPI with the RATCOM flow cytometer. Methods Cell. Biol., 33: 111-119, 1990.
30. Clark, G. M., Mathieu, M-C., Owens, M. A., Dressler, L. G., Eudey, L., Tormey, D. C., Osborne, C. K., Gilchrist, W., Mansour, E. G., Abeloff, M. D., and McGuire, W. L. Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J. Clin. Oncol., 10: 428-432, 1992.
31. Ranelletti, F. O., Scambia, G., Benedetti Panici, P., Piantelli, M., Ferrandina, G., D'Agostino, G., De Vincenzo, R., Rinelli, A., Isola, G., and Mancuso, S. Methyl-p-hydroxyphenyllactate esterase (MeHPLAase), and type II estrogen-binding sites in ovarian cancer: correlation with biological and clinicopathological parameters. Int. J. Cancer, 62: 536-541, 1995.
32. Weibull, W. A statistical distribution function of wide applicability. J. Appl. Mech., 18: 293-297, 1951.
33. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
34. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer. Chemother. Rep., 50: 163-170, 1966.
35. Cox, D. R. Regression models and life-tables. J. R. Stat. Soc. (B), 34: 187-220, 1972.
36. McGuire, W. L., Tandon, A. K., Allred, D. C., Chamness, G. C., Ravdin, P. M., and Clark, G. M. Prognosis and treatment decision in patients with breast cancer without axillary node involvement. Cancer (Phila.), 70: 1775-1781, 1992.